Sanofi to acquire BTK inhibitor firm Principia for $3.7 billion
Friday, August 21, 2020 - 18:51
in Health & Medicine
Principia is testing its small-molecule compounds in multiple sclerosis and immune system diseases
Principia is testing its small-molecule compounds in multiple sclerosis and immune system diseases